Td Asset Management Inc Adverum Biotechnologies, Inc. Transaction History

Td Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$3.36 - $10.56 $214,458 - $674,013	-63,827 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$9.26 - $14.36 $118,768 - $184,181	12,826 Added 25.15%	63,827 $629,000
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $73,800 - $106,950	7,500 Added 17.24%	51,001 $553,000
Q3 2020 Nov 10, 2020	SELL	$10.3 - $21.64 $309,000 - $649,200	-30,000 Reduced 40.82%	43,501 $448,000
Q2 2020 Aug 13, 2020	BUY	$8.53 - $25.64 $8,214 - $24,691	963 Added 1.33%	73,501 $1.54 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $127,584 - $260,924	15,988 Added 28.27%	72,538 $709,000
Q4 2019 Feb 11, 2020	SELL	$5.12 - $12.22 $18,944 - $45,214	-3,700 Reduced 6.14%	56,550 $651,000
Q3 2019 Nov 07, 2019	BUY	$5.24 - $15.89 $239,206 - $725,378	45,650 Added 312.67%	60,250 $328,000
Q2 2019 Aug 01, 2019	BUY	$5.1 - $11.89 $74,460 - $173,594	14,600 New	14,600 $174,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.